Stock fact sheet · data as of

BGM Group Ltd. (BGM): fair value, margin of safety and Wheel Score

Healthcare · Drug Manufacturers - Specialty & Generic · China · Speculative / Distressed

Close8.59
GLS fair value6.821 of 9 models
Margin of safety-26%price above fair value
Wheel Score7No optionscapped: no options
Health0/9Piotroski F-score
Moat1.0/10GLS 10-year score
Market cap$109M1k shares a day
Implied vol.-no listed options
P/E-EPS -3.42
Dividend yieldnone
Beta1.87moves more than the market
Next earnings-no date recorded

Is BGM undervalued?

BGM closed at 8.59 on 16 Oct 2026, which is 26% above the GLS average fair value of 6.82 from 1 models. 1 of them value the shares below today's price. Our screens read that as "no margin of safety": the stock is not a value candidate at this price, whatever the quality numbers say.

Only 1 of the nine models produced a value (10 Cap); the others need a dividend, positive free cash flow or positive book value the company does not have yet, so the average rests on a narrow base.

The nightly engine files BGM under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.

Nine valuation models for BGM

Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.

ModelValuevs priceWhat it measures
DCF--Present value of the projected free cash flows, discounted at the cost of capital; no value tonight
Graham Number--The most a defensive investor pays for the earnings and book value per share; no value tonight
Graham Growth--Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight
Lynch--EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight
GLS Growth--EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight
10 Cap6.82-21%Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%
Payback Time--Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight
DDM--Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight
EPV--Earnings power value: current EPS capitalised at 9% with no growth; no value tonight
Zombie (liquidation)0.7779-91%Current assets less all liabilities, per share: the balance-sheet floor. Not in the average
Wall St target0.0000-100%Analysts' average 12-month price target. Not in the average

Quality and financial health

Financial health is weak: BGM passes 0 of the nine Piotroski tests. Our screens drop the stock at the health rule; a low score is often the reason a stock looks cheap on the valuation models. The GLS Moat score is low at 1.0 out of 10, which says the ten-year record of revenue, earnings, margins and returns on capital has been inconsistent - growth and shocks rather than steady compounding.

Returns on capital are thin or negative - ROIC -5.1%, ROE -5.1%, ROA -4.6% - with debt at 0.00 times equity and a free-cash-flow yield of 1.3%.

BGM Group Ltd. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain.

Institutional ownership scores 1/10, insider activity 5/10 and Congressional trading 5/10 on the GLS smart-money scales.

Piotroski F-score0 / 9ROIC-5.1%
GLS Moat1.0 / 10ROE-5.1%
Debt / equity0.00ROA-4.6%
Free-cash-flow yield1.3%Payout ratio0%
Institutions1 / 10Insiders · Congress5 · 5 / 10

Wheel Score 7: No options

BGM has no listed options in the nightly snapshot, so there is nothing to sell and the stock cannot be wheeled however good the business; the Wheel Score is capped at 39 and shown as "No options" (7 here). The valuation and quality numbers still apply to owning the shares outright.

Volume runs at 1k shares a day on a market cap of $109M, with a beta of 1.87 - a high beta, so the stock tends to move more than the market and a strike can be gapped through; the Stability part of the Wheel Score gives that 4 of 20.

PartPointsFrom
Value2 / 25-26% margin of safety
Health0 / 20Piotroski 0/9
Moat2 / 15moat 1.0/10
Premium0 / 20no option data
Stability4 / 201k shares/day, $109M cap, beta 1.87

The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.

Upcoming events

No upcoming earnings date is recorded for BGM in the nightly calendar.

Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.

Similar stocks in Drug Manufacturers - Specialty & Generic

The 12 companies below are the closest to BGM Group Ltd. by market cap within the Drug Manufacturers - Specialty & Generic industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.

StockCloseFair valueMoSWheelMkt cap
CPIX
Cumberland Pharmaceuticals Inc.
7.5422.07+66%45Weak$113M
OGI
Organigram Global Inc.
0.931613.02+93%55Fair$131M
CRDL
Cardiol Therapeutics Inc.
1.150.1478-678%21Weak$139M
ORGO
Organogenesis Holdings Inc.
1.114.16+73%45Weak$143M
AAWH
Ascend Wellness Holdings, Inc.
0.40504.17+90%39No options$82M
DERM
Journey Medical Corporation
5.13--37Weak$145M
ZYBT
Zhengye Biotechnology Holding Limited
1.5310.85+86%36No options$73M
INCR
InterCure Ltd.
4.656.18+25%45Weak$55M
TLPH
Talphera, Inc.
1.06--32Weak$55M
SIGA
SIGA Technologies, Inc.
3.108.72+64%45Weak$223M
LFCR
Lifecore Biomedical, Inc.
6.44--45Weak$244M
ACB
Aurora Cannabis Inc.
4.10--45Weak$260M

⚖ Compare BGM with 7 of them   All Healthcare stocks →

Screen the whole market the same way

A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.

Start free See the Sunday Scan

Questions about BGM

Is BGM undervalued right now?

No: at 8.59 the stock trades 26% above the GLS average fair value of 6.82 (data as of 16 Oct 2026). The margin of safety is negative.

What is the Wheel Score of BGM and what does it mean?

BGM has no listed options in our nightly snapshot, so it cannot be wheeled; its Wheel Score is capped at 39 and shown as "No options".

What is the GLS fair value for BGM?

6.82 per share as of 16 Oct 2026 - the simple average of the 1 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.

When does BGM Group Ltd. report earnings next?

No upcoming earnings date is recorded for BGM in our calendar as of 16 Oct 2026; the Calendars page is refreshed every morning.

Does BGM have listed options, and how liquid are they?

No. The nightly options snapshot found no listed contracts on BGM, so the wheel strategy cannot be run on it and the Wheel Score is capped at 39.

Data as of 16 Oct 2026: prices and fundamentals from Financial Modeling Prep, option data from Polygon; valuations, scores and the Wheel Score by GLS Equity's models, run nightly. Prices in USD; the close shown is the previous session's. Everything on this page is general information produced by automated models from third-party data - not a recommendation to buy, sell or trade any security or option, and not financial advice. Past performance is not indicative of future results. GLS Equity provides data and tools, not financial advice.